ACIP Recommendations
The ACIP develops recommendations on how to use vaccines to control disease in the United States.
The Committee’s recommendations are forwarded to CDC’s Director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC Director, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.
- ACIP Recommendations
Complete list of ACIP recommendations published in the MMWR. - Immunization Schedules
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms. - ACIP Shared Clinical Decision-Making FAQs
Frequently asked questions about ACIP’s recommendations based on shared clinical decision-making
February 2023
ACIP approved the following recommendation by majority vote at its February 22-24, 2023 meeting:
- ACIP recommends the 2-dose* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak§.
*Dose 2 administered one month after dose 1
§Public health authorities determine whether there is an mpox outbreak; a single case may be considered an mpox outbreak at the discretion of public health authorities. Other circumstances in which a public health response may be indicated include ongoing risk of introduction of mpox into a community due to disease activity in another geographic area.
This recommendation has been adopted by the CDC Director and is now official. It will be published in MMWR in the coming months.
October 2022
ACIP approved the following recommendations by majority vote at its October 19-20, 2022 meeting:
- Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2023 and Recommended Adult Immunization Schedule, United States, 2023.
- Adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak who have received both PCV13 and PPSV23 with incomplete vaccination status are recommended to complete their pneumococcal vaccine series by receiving either a dose of PCV20 at least 5 years after the last pneumococcal vaccine dose or PPSV23 as previously recommended.
- Shared clinical decision-making is recommended regarding administration of PCV20 for adults aged ≥65 years who completed their vaccine series with both PCV13 and PPSV23. If a decision to administer PCV20 is made, a dose of PCV20 is recommended at least 5 years after the last pneumococcal vaccine dose.
- Adults who have received PCV13 only are recommended to receive a dose of PCV20 at least 1 year after the PCV13 dose or PPSV23 as previously recommended to complete their pneumococcal vaccine series.
These recommendations have been adopted by the CDC Director and are now official. They will be published in MMWR in the coming months.